98 related articles for article (PubMed ID: 3934802)
21. Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.
Bennett B; Forman WB; Ratnoff OD
J Clin Invest; 1973 Sep; 52(9):2191-7. PubMed ID: 4199413
[TBL] [Abstract][Full Text] [Related]
22. Inactivation of viruses in red cell and platelet concentrates with aluminum phthalocyanine (AIPc) sulfonates.
Horowitz B; Rywkin S; Margolis-Nunno H; Williams B; Geacintov N; Prince AM; Pascual D; Ragno G; Valeri CR; Huima-Byron T
Blood Cells; 1992; 18(1):141-9; discussion 150. PubMed ID: 1617188
[TBL] [Abstract][Full Text] [Related]
23. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
25. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
[No Abstract] [Full Text] [Related]
26. Hepatitis C virus RNA in factor VIII concentrates.
Guo ZP; Yu MW
Transfusion; 1995 Feb; 35(2):112-6. PubMed ID: 7825205
[TBL] [Abstract][Full Text] [Related]
27. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
28. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
29. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
31. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
[TBL] [Abstract][Full Text] [Related]
32. Virus inactivation by heat treatment of lyophilized coagulation factor concentrates.
Piszkiewicz D; Thomas W; Lieu MY; Tse D; Sarno L
Curr Stud Hematol Blood Transfus; 1989; (56):44-54. PubMed ID: 2491984
[No Abstract] [Full Text] [Related]
33. Recovery and inactivation of infectious retroviruses from factor VIII concentration.
Levy JA; Mitra G; Mozen MM
Lancet; 1984 Sep; 2(8405):722-3. PubMed ID: 6148474
[TBL] [Abstract][Full Text] [Related]
34. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
[TBL] [Abstract][Full Text] [Related]
35. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
[TBL] [Abstract][Full Text] [Related]
36. The influence of pH on heat denaturation of anti-haemophilic cryoprecipitate.
Skjønsberg OH; Gravem K; Kierulf P; Vaeret A; Godal HC
Thromb Res; 1987 Jul; 47(2):183-90. PubMed ID: 3116715
[TBL] [Abstract][Full Text] [Related]
37. Heat stability of the lyophilized Sabin poliovaccine.
Shiomi H; Urasawa T; Urasawa S
Jpn J Infect Dis; 2003 Apr; 56(2):70-2. PubMed ID: 12824691
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.
Spire B; Dormont D; Barré-Sinoussi F; Montagnier L; Chermann JC
Lancet; 1985 Jan; 1(8422):188-9. PubMed ID: 2857267
[TBL] [Abstract][Full Text] [Related]
39. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
Orthner CL
J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
[TBL] [Abstract][Full Text] [Related]
40. ANTIHEMOPHILIC FACTOR: ITS PRESENCE IN FIBRINOGEN, ASSAY PROBLEMS AND THE STABILITY OF LYOPHILIZED AHF-FIBRINOGEN PREPARATIONS.
BAUMGARTEN W; SANDERS BE; BELKIN BD; PAGENKEMPER FE; ALBERS WG; CIMINERA JL
Thromb Diath Haemorrh; 1963 Jul; 143():354-67. PubMed ID: 14081259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
